Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule

被引：0
|
作者：
Agustin A. Garcia
Mahesh Pujari
Susan Jeffers
Syma Iqbal
Heinz-Josef Lenz
Paul Beringer
Stan Louie
机构：
[1] University of Southern California,Norris Comprehensive Cancer Center, Keck School of Medicine
[2] University of Southern California,School of Pharmacy
[3] Women’s Cancer Research Institute,Cedars Sinai Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2005年 / 56卷
关键词：
Phase I; Clinical trial; Pharmacokinetics; Docetaxel; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 82
页数：7
相关论文
共 50 条
  • [41] PHASE-I TRIAL AND BIOCHEMICAL EVALUATION OF TIAZOFURIN ON A WEEKLY SCHEDULE
    MELINK, T
    VONHOFF, D
    PHILLIPS, J
    SAROSY, G
    GREVER, M
    JAYARAM, H
    WHITECAR, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 173 - 173
  • [42] A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly
    Dawson, LK
    Jodrell, DI
    Bowman, A
    Rye, R
    Byrne, B
    Bernareggi, A
    Camboni, G
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) : 2353 - 2359
  • [43] Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A (CSA).
    Fagbemi, S
    Ratain, MJ
    Iyer, L
    Mani, S
    Vogelzang, NJ
    Wang, X
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 163 - 163
  • [44] Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer
    Stevenson, JP
    Redlinger, M
    Kluijtmans, LAJ
    Sun, WJ
    Algazy, K
    Giantonio, B
    Haller, DG
    Hardy, C
    Whitehead, AS
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (20) : 4081 - 4087
  • [45] A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
    Dy, GK
    Mandrekar, S
    Peethambaram, PP
    Okuno, SH
    Croghan, GC
    Hanson, LJ
    Furth, A
    Adjei, AA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (06) : 623 - 628
  • [46] A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
    Grace K. Dy
    Sumithra Mandrekar
    Prema P. Peethambaram
    Scott H. Okuno
    Gary C. Croghan
    Lorelei J. Hanson
    Alfred Furth
    Alex A. Adjei
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 623 - 628
  • [47] A PHASE-I TRIAL OF SPIROGERMANIUM ADMINISTERED ON A CONTINUOUS INFUSION SCHEDULE
    WOOLLEY, PV
    AHLGREN, JD
    BYRNE, PJ
    PRIEGO, VM
    SCHEIN, PS
    INVESTIGATIONAL NEW DRUGS, 1984, 2 (03) : 305 - 309
  • [48] A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer.
    Rathkopf, D
    Fornier, M
    Shah, MA
    Kortmansky, J
    O'Reilly, E
    Winkelmann, J
    Balzano, L
    Kelsen, DP
    Schwartz, GK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 331S - 331S
  • [49] PHASE-I CLINICAL AND PHARMACOKINETIC TRIAL OF ORAL MENOGARIL ADMINISTERED ON 3 CONSECUTIVE DAYS
    DODION, P
    DEVALERIOLA, D
    CRESPEIGNE, N
    PEETERS, B
    WERY, F
    VANBERCHEM, C
    PICCART, M
    TUENI, E
    LOGGI, J
    KENIS, Y
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (06): : 1019 - 1026
  • [50] Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors
    Kuppens, IELM
    Dansin, E
    Boot, H
    Feger, C
    Assadourian, S
    Bonneterre, ME
    Beijnen, JH
    Schellens, JHM
    Bonneterre, J
    CLINICAL CANCER RESEARCH, 2006, 12 (12) : 3774 - 3781
12345